These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21907552)

  • 21. New perspectives in the treatment of neuroendocrine tumours.
    Bajetta E; Catena L; Valente M; Bianco N; Bellomo F; Bombardieri E
    Anticancer Res; 2012 Oct; 32(10):4193-200. PubMed ID: 23060539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
    Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
    Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of advanced neuroendocrine tumors with hepatic metastasis.
    Khasraw M; Gill A; Harrington T; Pavlakis N; Modlin I
    J Clin Gastroenterol; 2009 Oct; 43(9):838-47. PubMed ID: 19654558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T; Lee L; Jensen RT
    Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
    Anthony L; Vinik AI
    Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
    Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine tumours - Medical therapy: Biological.
    Rinke A; Krug S
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system].
    Hörsch D; Sayeg Y; Bonnet R; Kaemmerer D; Presselt N; Baum RP
    Pneumologie; 2012 Jan; 66(1):44-8. PubMed ID: 22250054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current medical treatment of pancreatic neuroendocrine tumors.
    Yalcin S; Oyan B; Bayraktar Y
    Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.
    Khasraw M; Townsend A; Price T; Hart J; Bell D; Pavlakis N
    Intern Med J; 2010 Jun; 40(6):453-8. PubMed ID: 20636828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
    Modlin IM; Pavel M; Kidd M; Gustafsson BI
    Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.
    Di Giacinto P; Rota F; Rizza L; Campana D; Isidori A; Lania A; Lenzi A; Zuppi P; Baldelli R
    Int J Endocrinol; 2018; 2018():8126087. PubMed ID: 30057604
    [No Abstract]   [Full Text] [Related]  

  • 37. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review.
    Srirajaskanthan R; McStay M; Toumpanakis C; Meyer T; Caplin ME
    Neuroendocrinology; 2009; 89(1):48-55. PubMed ID: 18679021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
    Simonenko VB; Dulin PA; Makanin MA
    Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expanding role of somatostatin analogs in the management of neuroendocrine tumors.
    Wolin EM
    Gastrointest Cancer Res; 2012 Sep; 5(5):161-8. PubMed ID: 23112884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.